Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...
Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...
Exidavnemab is being developed as a potential disease-modifying treatment, aiming to halt or slow the progression of ...
BioArctic AB (publ), a Swedish research-based biopharma company, announced that the first patient has been dosed with exidavnemab in the EXIST phase 2a study, in Parkinson’s disease patients.
People with Parkinson's who have taken part in drum lessons have seen a "tangible difference" in their mobility, according to ...
Funding has been made available which will enable new research to take place into a possible link between manganese exposure ...
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders including ...